SEC Form 4 · accession 0001140361-18-028996
Loxo Oncology, Inc. · LOXO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lori Anne Kunkel
Director
Period of report
Jun 14, 2018
Accepted (ET)
Jun 18, 2018 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 14, 2018 | M | 27,343 | $3.648 | A | 34,183 | D | |
| Common Stock | Jun 14, 2018 | M | 3,096 | $20.91 | A | 37,279 | D | |
| Common Stock | Jun 14, 2018 | M | 1,953 | $24.18 | A | 39,232 | D | |
| Common StockF1,F2 | Jun 14, 2018 | S | 28,440 | $180.2751 | D | 10,792 | D | |
| Common StockF1,F3 | Jun 14, 2018 | S | 2,411 | $181.4783 | D | 8,381 | D | |
| Common StockF1,F4 | Jun 14, 2018 | S | 1,541 | $182.3467 | D | 6,840 | D | |
| Common StockF1,F6 | Jun 15, 2018 | S | 1,235 | $175.6434 | D | 5,605 | D | |
| Common StockF1,F7 | Jun 15, 2018 | S | 5,601 | $177.1217 | D | 4 | D | |
| Common Stock | Jun 15, 2018 | S | 4 | $177.79 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F8 | $3.648 | Jun 14, 2018 | M | 27,343 | D | — | Jun 18, 2024 | Common Stock | 27,343 | 27,344 | D |
| Director Stock Option (right to buy)F9 | $20.91 | Jun 14, 2018 | M | 3,096 | D | — | Jul 27, 2025 | Common Stock | 3,096 | 4,716 | D |
| Director Stock Option (right to buy)F9 | $24.18 | Jun 14, 2018 | M | 1,953 | D | — | Jun 9, 2026 | Common Stock | 1,953 | 5,859 | D |
Explanation of responses
- F1Represents the aggregate of sales effected on the same day at different prices
- F2Represents the weighted average sales price per share. The shares sold at prices ranging from $180.00 to $180.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3Represents the weighted average sales price per share. The shares sold at prices ranging from $181.01 to $181.92 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4Represents the weighted average sales price per share. The shares sold at prices ranging from $182.31 to $182.83 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F5The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017.
- F6Represents the weighted average sales price per share. The shares sold at prices ranging from $175.36 to $176.10 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F7Represents the weighted average sales price per share. The shares sold at prices ranging from $176.68 to $177.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F8The stock option is fully vested and is immediately exercisable.
- F9The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.